|Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
We investigated the diagnostic and therapeutic methods for atherosclerotic plaque rapture in clinics. We had already reported the observational research results ; coronary arterial lesions and thrombus following sirolimus-eluting stent implantation assessed by optical coherence tomography, Effect of some drugs on the stability of coronary atherosclerotic plaques. Moreover, we developed some of the new anti-inflammatory therapies against atherosclerosis in basic experiments using mouse. We united the clinical and basical research results and discovered the drug's beneficial mechanism that the drug regressed atherosclerotic lesions or stabilized the lesions in clinical research. We could not discover the new marker for predicting the atherosclerotic plaque rapture, so far.